-
Citation of Cloud-Clone products in Apr. 2019 (Excerpt)
In April. 2019, 230 SCI articles have been published related with Cloud-Clone products. The products from Cloud-Clone have been well received by customers worldwide.Cat. No.TargetsSpeciesMagazine NameIFPubmed/DOIAuthor informationSEA004HuACEHumanIntensive Care Medicine15.00810.1007/s00134-019-05600-6Department of Intensive Care, Erasme University HospitalUniversité Libre de BruxellesBrusselsBelgiumSEB886HuACE2PAB389Hu01vWA2HumanAdvanced Science12.44110.1002/advs.201802115Asan Institute for Life Sciences, Asan Medical Center, 88 Olympic‐ro 43‐gil, Songpa‐gu, Seoul, 05505 Republic of KoreaSEA181MuNEMouseJournal of Pineal Research11.61330929267Beijing Advanced Innovation Center for......
-
Literature of Cloud Clone products in Mar 2019 (Excerpt)
In Mar 2019, Literature of Cloud Clone products has exceeded 220. Cloud-Clone could provide multipleproteins,antibodies and ELISA kits, which has been praised by customers.Cat. No.TargetsSpeciesMagazine NameIFPubmed/DOIAuthor informationCAB340Hu22ACTBHumanCell Metabolism20.56510.1016/jNaNet.2019.01.021Diabetes Center, University of California, San Francisco, San Francisco, CA 94143, USASEB785HuCD10HumanEuropean Journal of Heart Failure10.68330828920Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna.CEB979MuHepcMouseHaematologica9.0930792208SKLECE, RCEES, CAS, Beijing 100085, China.CEC036MuTFSEA518MuFESEB750MuTNFSF13MouseHaematologica9.09308......
-
Literature of Cloud Clone products in Feb 2019 (Excerpt)
In Feb 2019, Literature of Cloud Clone products has exceeded 210. Cloud-Clone could provide multipleproteins, antibodies and ELISA kits, which has been praised by customers.Cat. No.TargetsSpeciesMagazine NameIFPubmed/DOIAuthor informationSED116MuIHHMouseJournal of Hepatology15.0430711403Rudolf-Schönheimer-Institute of Biochemistry, Faculty of Medicine, University of Leipzig,Germany.CEA908GeMTGeneralJournal of Pineal Research11.61330715754Department of Cardiovascular Medicine, Fukushima Medical University, Fukushima, Japan.MEL154MuFGF15MouseDevelopmental Cell9.61630745141State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Scienc......
-
TGFb1 - an angel or a devil?
TGFb1 - An angel or a devil?Recently, researchers found thatTransforming Growth Factor beta 1(TGFb1) has two sidesin tumor.It is a tumor suppressor through decreasingthe proliferation of cancer cells, but in the mean while, it is also a tumor promoter by promoting formation of tumor micro-environment which benefits the growth, infiltration and transfer of tumor cells.Next, we will make a brief introduction of the regulating function of TGFb1 in tumor, its clinical value and quantification method.TGFb1 belongs to TGFb subfamily, this family also includes TGFb2, TGFb3, TGFb4, et al. Proteins in TGFb subfamily are multifunctional, they regulate cell growth and differentiation in body. ......
-
PINP: A new clinical diagnostic marker of bone metabolism related diseases -Cloud-Clone product reappeared on Nature
Keywords: PINP; Bone metabolism; Tumor; Clinical diagnosisWith the increasingof elderly populationin the world, bone metabolism related diseases have become one of the top ten common diseases. Therefore, bone metabolism is a hotspot in medical researches.More and more researchers and clinicians began to look for clinical diagnostic markers of bone metabolism related diseases.Currently, a large number of studies have shown that PINP (Procollagen I N - Terminal Propeptide), a bone formation marker, is closely related to a variety of bone metabolic diseases, tumor bone metastasis and multiple myeloma.And its detection is not affected by food, circadian rhythm, hormones and other interfere......
-
The key of Neurodegenerative diseases reverse growth - the differentiation of nerve cells
Neurodegenerative diseases are associated with the loss of neurons and/or the myelin sheaths. The disease worsens as time goes on, and leading to dysfunction. Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD) and Amyotrophic Lateral Sclerosis (ALS) are the most common neurodegeneration diseases.For a long time, people thought that once nerve cells in the brains of adult mammals are damaged, they are unable to regenerate. This thought led to the major limitation in the treatment of neurodegenerative diseases. The principle of current treatment is to improve symptoms and slow the progression of the disease. In recent years, great progress has been ......